Chris is a Senior Research Development Manager at the MBHI with over 14 years of experience in grant administration, interdisciplinary collaboration, and proposal development. A 2024 ASGII “Rising Star” Award recipient, he has secured multi-million-dollar funding and is recognized for his leadership, mentorship, and team training.
Have a Brain Health Project in Mind?
Whether you’re looking to explore an idea, discuss possibilities, or get guidance on developing your project, we’re here to help.
Spotlight Funding Opportunity
The National Institutes of Health (NIH) is currently accepting applications under PAR-25-331, designed to support exploratory and developmental research on Alzheimer’s disease (AD) and related dementias (ADRD).
PAR-25-331 invites proposals for innovative research projects that address critical, current topics in AD/ADRD. The goal is to accelerate understanding of dementia via new models, tools, technologies, or study designs that need pilot data to become broadly useful to the field.
The grant encourages biomedical, social, and behavioral research aimed at unraveling the complex mechanisms underlying AD/ADRD and aging-related brain disorders.
Key Dates
- First submission window opens: February 11, 2025
- Standard receipt dates recur every four months (June, October, February, etc.) through October 16, 2027.
- Applications are due by 5:00 PM local time on each receipt date.
Grant Details
- Activity code: R21 (Exploratory/Developmental Grant)
- Project period: Up to 2 years
- Combined direct-cost budget limit: $275,000 over the full project period — with no more than $200,000 in direct costs allowed in any single year.
- Clinical trial optional.
Detailed guidelines and submission portal:
Past Human Brain Talk
Ara is a Senior Research Development Manager at the MBHI, specializing in grant writing, publications, and program management. With a background in neuroscience, microbiology, and military journalism, he has co-authored numerous scientific papers, secured multi-million-dollar grants, and previously supported infectious disease research at the GNL.
